BALTIMORE, May 1, 2012 /PRNewswire/ -- Ameritox, the national leader in pain-medication monitoring, calls attention to the Millennium Laboratories statements issued in their April 30, 2012 press release ( http://www.prnewswire.com/news-releases/millennium-laboratories-commends-floridas-governor-scott-for-strengthening-regulation-of-clinical-laboratories-149472985.html). The Millennium Laboratories press release suggests Florida Governor Rick Scott's signing of House Bill 787 supports their position on clinical laboratory operation while disregarding the Governor's public position. Comparison of the Millennium Laboratories April 30, 2012 press release alongside Governor Scott's April 27, 2012 letter to Florida Secretary of State Ken Detzner provides a clear example of this discrepancy. "Millennium's tactics in the marketplace are not acceptable," said Ancelmo Lopes, chief executive officer, Ameritox. "It is not our interest to mention other companies in public communications; however, we will not let these statements go unanswered when it comes to something as important as patient well-being." Governor Scott's Official Signing Letter Cites Section 35 Concerns Though Millennium Laboratories suggests that Governor Scott supports their company's position specifically, House Bill 787 covers a wide array of health care facilities needs – not just how and where drug testing is conducted. Examination of facts demonstrates Millennium Laboratories does not fully convey the Governor's on-record concerns. In an April 27, 2012 letter to Secretary Detzner, Governor Scott states: "While I find most of the bill's provisions very positive, I do have concerns about the language in Section 35 of the bill amending Section 483.245, Florida Statutes. It is critically important for the state to maintain a strict prohibition against unlawful commissions, bonuses, kickbacks, rebates or split fee arrangements. However, the current interpretation of the anti-kickback law as it relates to the use of trained specimen collectors and the lease of space in the physician offices merits further scrutiny. To that end, I will direct the Secretary of the Agency for Health Care Administration to work with representatives of the clinical lab industry to examine this issue and develop alternative approaches to regulating this particular area of health care law." Ameritox is encouraged by the Governor's letter to Secretary Detzner and, as the national leader in medication monitoring, looks forward to the opportunity to work collaboratively with AHCA and other leading clinical laboratories on this issue crucial to patients suffering from chronic pain.